Evolving Challenges in Promoting Cardiovascular Health, Volume 1254
1st Edition
Will be published approx. on 10. July 2012
Book
Paperback/Softback
252 pages
978-1-57331-859-4 (ISBN)
Description
This Annals volume stems from the two-day conference "Evolving Challenges in Promoting Cardiovascular Health" sponsored by The New York Academy of Sciences, "la Caixa" Foundation, and the International Center for Scientific Debate (ICSD), which took place November 4-5, 2011 in Barcelona, Spain. Leading and emerging investigators working on the fields of cardiology, vascular disease, inflammation, metabolic disorders, hematology, imaging, regenerative medicine, stem cell research, epidemiology, and nutrition, among others, address novel issues, current challenges, and future directions in the prevention, treatment, and management of the evolving global epidemic of cardiovascular disease. The papers in this volume explore the promotion of cardiovascular health through molecular biology, clinical pathophysiology, and population research.
NOTE: Annals volumes are available for sale as individual books or as a journal. For information on institutional journal subscriptions, please visit http://ordering.onlinelibrary.wiley.com/subs.asp?ref=1749-6632&doi=10.1111/(ISSN)1749-6632.
ACADEMY MEMBERS: Please contact the New York Academy of Sciences directly to place your order (www.nyas.org). Members of the New York Academy of Science receive full-text access to Annals online and discounts on print volumes. Please visit http://www.nyas.org/MemberCenter/Join.aspx for more information about becoming a member.
NOTE: Annals volumes are available for sale as individual books or as a journal. For information on institutional journal subscriptions, please visit http://ordering.onlinelibrary.wiley.com/subs.asp?ref=1749-6632&doi=10.1111/(ISSN)1749-6632.
ACADEMY MEMBERS: Please contact the New York Academy of Sciences directly to place your order (www.nyas.org). Members of the New York Academy of Science receive full-text access to Annals online and discounts on print volumes. Please visit http://www.nyas.org/MemberCenter/Join.aspx for more information about becoming a member.
More details
Series
Language
English
Place of publication
Hoboken
United Kingdom
Publishing group
John Wiley and Sons Ltd
Target group
Professional and scholarly
Product notice
Paperback (trade)
Unsewn / adhesive bound
Dimensions
Height: 251 mm
Width: 175 mm
Thickness: 10 mm
Weight
386 gr
ISBN-13
978-1-57331-859-4 (9781573318594)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Person
Valentin Fuster, MD, PhD, former Chairman of the American Heart Association's Committee on Vascular Lesions, Assessing and Modifying the Vulnerable Atherosclerotic Plaque explores the most cutting-edge developments in a field grown richer through technological advances.
Content
1. Cardiovascular defense challenges at the basic, clinical, and population levels
Jason C. Kovacic, Jose M. Castellano, and Valentin Fuster
7. Plaque neovascularizationl defense mechanisms, betrayal, or a war in progress
Pedro R. Moreno, Meeranani Purushothaman, and K-Raman Purushothaman
18. LDL-cholesterol versus HDL-cholesterol in the atherosclerotic plaque: inflammatory resolution versus thrombotic chaos
Lina Badimon and Gemma Vilahur
33. Evolving role of molecular imaging for new understanding: targeting myofibroblasts to predict remodeling
Hans J. de Haas, Susanne W. van den Borne, Hendrikus H. Boersma, Riemer H.J.A. Slart, Valentin Fuster, and Jagat Narula
42. Molecular targets in heart failure gene therapy: current controversies and translational perspectives
Victor Kairouz, Larissa Lipskaia, Roger J. Hajjar, and Elie R. Chemaly
51. Engineered arterial models to correlate blood flow to tissue biological response
Jordi Martorell, Pablo Santoma, Jose J. Molins, Andres A. Garcia-Granada, Jose A. Bea, Elazer R. Edelman, and Mercedes Balcells
57. A bird's-eye view of cell therapy and tissue engineering for cardiac regeneration
Carolina Soler-Botija, Juli R. Bago, and Antoni Bayes-Genis
66. Umbilical cord blood for cardiovascular cell therapy: from promise to fact
Santiago Roura, Josep-Maria Pujal, and Antoni Bayes-Genis
71. Heart repair: from natural mechanisms of cardiomyocyte production to the design of new cardiac therapies
Silvia Martin-Puig, Valentin Fuster, and Miguel Torres
82. Energy metabolism plasticity enables stemness programs
Clifford D.L. Folmes, Timothy J. Nelson, Petras P. Dzeja, and Andre Terzic
90. The future: therapy of myocardial protection
David Sanz-Rosa, Jaime Garcia-Prieto, and Borja Ibanez
99. The links between complex coronary disease, cerebrobascular disease, and degenerative brain disease
Jason C. Kovacic, Jose M. Castellano, and Valentin Fuster
106. Optimal lipid targets for the new era of cardiovascular prevention
Vimal Ramjee, danny J. Eapen, and Laurence S. Sperling
115. Controversies in blood pressure goal guidelines and masked hypertension
Robert A. Phillips
123. Evolving diagnostic and prognostic imaging of the various cardiomyopathies
Javier Sanz
131. The evolving landscape of quality measurement for heart failure
Ashley A. Fitzgerald, Larry A. Allen, and Frederick A. Masoudi
140. Atrial Fibrillation, Stock, and quality of life
Jason S. Chinitz, Jose M. Castellano, Jason C. Kovacic, and Valentin Fuster
151. Transcatheter aortic valve implantation and cerebrovascular events: the current state of the art
Brian G. Hynes and Josep Rodes-Cabau
164. Are we ignoring the dilated thoracic aortia?
Jose M. Castellano, Jason C. Kovacic, Javier Sanz, and Valentin Fuster
175. Corrigendum
Jason C. Kovacic, Jose M. Castellano, and Valentin Fuster
7. Plaque neovascularizationl defense mechanisms, betrayal, or a war in progress
Pedro R. Moreno, Meeranani Purushothaman, and K-Raman Purushothaman
18. LDL-cholesterol versus HDL-cholesterol in the atherosclerotic plaque: inflammatory resolution versus thrombotic chaos
Lina Badimon and Gemma Vilahur
33. Evolving role of molecular imaging for new understanding: targeting myofibroblasts to predict remodeling
Hans J. de Haas, Susanne W. van den Borne, Hendrikus H. Boersma, Riemer H.J.A. Slart, Valentin Fuster, and Jagat Narula
42. Molecular targets in heart failure gene therapy: current controversies and translational perspectives
Victor Kairouz, Larissa Lipskaia, Roger J. Hajjar, and Elie R. Chemaly
51. Engineered arterial models to correlate blood flow to tissue biological response
Jordi Martorell, Pablo Santoma, Jose J. Molins, Andres A. Garcia-Granada, Jose A. Bea, Elazer R. Edelman, and Mercedes Balcells
57. A bird's-eye view of cell therapy and tissue engineering for cardiac regeneration
Carolina Soler-Botija, Juli R. Bago, and Antoni Bayes-Genis
66. Umbilical cord blood for cardiovascular cell therapy: from promise to fact
Santiago Roura, Josep-Maria Pujal, and Antoni Bayes-Genis
71. Heart repair: from natural mechanisms of cardiomyocyte production to the design of new cardiac therapies
Silvia Martin-Puig, Valentin Fuster, and Miguel Torres
82. Energy metabolism plasticity enables stemness programs
Clifford D.L. Folmes, Timothy J. Nelson, Petras P. Dzeja, and Andre Terzic
90. The future: therapy of myocardial protection
David Sanz-Rosa, Jaime Garcia-Prieto, and Borja Ibanez
99. The links between complex coronary disease, cerebrobascular disease, and degenerative brain disease
Jason C. Kovacic, Jose M. Castellano, and Valentin Fuster
106. Optimal lipid targets for the new era of cardiovascular prevention
Vimal Ramjee, danny J. Eapen, and Laurence S. Sperling
115. Controversies in blood pressure goal guidelines and masked hypertension
Robert A. Phillips
123. Evolving diagnostic and prognostic imaging of the various cardiomyopathies
Javier Sanz
131. The evolving landscape of quality measurement for heart failure
Ashley A. Fitzgerald, Larry A. Allen, and Frederick A. Masoudi
140. Atrial Fibrillation, Stock, and quality of life
Jason S. Chinitz, Jose M. Castellano, Jason C. Kovacic, and Valentin Fuster
151. Transcatheter aortic valve implantation and cerebrovascular events: the current state of the art
Brian G. Hynes and Josep Rodes-Cabau
164. Are we ignoring the dilated thoracic aortia?
Jose M. Castellano, Jason C. Kovacic, Javier Sanz, and Valentin Fuster
175. Corrigendum